Ginkgo Bioworks Holdings (DNA)vsMerck & Company Inc (MRK)
DNA
Ginkgo Bioworks Holdings
$9.70
+14.66%
HEALTHCARE · Cap: $551.05M
MRK
Merck & Company Inc
$109.18
+2.73%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 38107% more annual revenue ($65.01B vs $170.16M). MRK leads profitability with a 28.1% profit margin vs -183.8%. MRK earns a higher WallStSmart Score of 59/100 (C).
DNA
Avoid29
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+33.4%
Fair Value
$14.03
Current Price
$9.70
$4.33 discount
Margin of Safety
-16.2%
Fair Value
$96.56
Current Price
$109.18
$12.62 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -51.1% — below average capital efficiency
Revenue declined 23.8%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : DNA
The strongest argument for DNA centers on Price/Book.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : DNA
The primary concerns for DNA are EPS Growth, Market Cap, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
DNA profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
DNA carries more volatility with a beta of 1.57 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 29/100), backed by strong 28.1% margins. DNA offers better value entry with a 33.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ginkgo Bioworks Holdings
HEALTHCARE · BIOTECHNOLOGY · USA
Ginkgo Bioworks Holdings (DNA) is a frontrunner in the synthetic biology industry, leveraging cutting-edge genetic engineering techniques to develop tailored bioengineered organisms for diverse applications in pharmaceuticals, agriculture, and industrial biotechnology. The company’s innovative platform enhances cellular design for manufacturing, optimizing product development and streamlining production processes. With a strong focus on solving critical global challenges, including climate change and food security, Ginkgo is well-positioned to influence multiple sectors while fostering sustainable advancements in biotechnology. As the industry evolves, Ginkgo's commitment to bio-based solutions positions it for significant growth and impact.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?